|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1996
|
|
gptkbp:atc_code
|
N06 DA02
|
|
gptkbp:brand
|
gptkb:donepezil_hydrochloride
|
|
gptkbp:chemical_formula
|
C24 H29 NO3
|
|
gptkbp:clinical_trial
|
donepezil long-term efficacy
donepezil vs placebo
|
|
gptkbp:contraindication
|
severe liver problems
allergy to donepezil
|
|
gptkbp:dosage_form
|
gptkb:tablet
10 mg once daily
orally disintegrating tablet
|
|
gptkbp:duration
|
daily
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:form
|
oral tablet
orally disintegrating tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aricept
|
|
gptkbp:ingredients
|
gptkb:donepezil
|
|
gptkbp:interacts_with
|
nonsteroidal anti-inflammatory drugs (NSAIDs)
anticholinergic drugs
other cholinesterase inhibitors
|
|
gptkbp:is_monitored_by
|
cognitive assessment
side effect reporting
|
|
gptkbp:manufacturer
|
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer_Inc.
|
|
gptkbp:market
|
monitoring for side effects
|
|
gptkbp:marketed_as
|
gptkb:Aricept_ODT
|
|
gptkbp:maximum_dose
|
10 mg
|
|
gptkbp:mechanism_of_action
|
acetylcholinesterase inhibitor
|
|
gptkbp:patient_education
|
take at bedtime
with or without food
|
|
gptkbp:patient_population
|
mild to moderate Alzheimer's disease
|
|
gptkbp:pharmacokinetics
|
metabolized in liver
oral absorption
half-life of 70 hours
|
|
gptkbp:previous_name
|
gptkb:donepezil
|
|
gptkbp:regulatory_compliance
|
gptkb:Health_Canada
gptkb:TGA_Australia
gptkb:European_Medicines_Agency
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
cognitive enhancement
Alzheimer's disease treatment
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
insomnia
muscle cramps
|
|
gptkbp:starting_dose
|
5 mg
|
|
gptkbp:treatment
|
enhance quality of life
improve cognitive function
slow cognitive decline
|
|
gptkbp:type_of_care
|
once daily dosing
|
|
gptkbp:used_for
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:bfsParent
|
gptkb:Eisai
|
|
gptkbp:bfsLayer
|
5
|